Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: Comparison between clopidogrel and low-dose aspirin
Background: Chronic kidney disease (CKD) coexisting with type 2 diabetes mellitus (DM) leads to coronary artery disease. The present study compares clopidogrel and low-dose aspirin as prophylactic therapy against coronary events in patients with CKD with diabetes. Methods: Total 80 patients of CKD...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
| Series: | International Journal of Preventive Medicine |
| Subjects: | |
| Online Access: | http://www.ijpvmjournal.net/article.asp?issn=2008-7802;year=2013;volume=4;issue=8;spage=902;epage=910;aulast=Dash |
| _version_ | 1818510745709576192 |
|---|---|
| author | Amitabh Dash Rituparna Maiti Tejaswi Kumar Akantappa Bandakkanavar Amit Bhaskar Jai Prakash Bajarang Lal Pandey |
| author_facet | Amitabh Dash Rituparna Maiti Tejaswi Kumar Akantappa Bandakkanavar Amit Bhaskar Jai Prakash Bajarang Lal Pandey |
| author_sort | Amitabh Dash |
| collection | DOAJ |
| description | Background: Chronic kidney disease (CKD) coexisting with type 2 diabetes mellitus (DM) leads to coronary artery disease. The present study compares clopidogrel and low-dose aspirin as prophylactic therapy against coronary events in patients with CKD with diabetes.
Methods: Total 80 patients of CKD with type 2 DM were randomized and allocated to clopidogrel and aspirin groups to receive the drug at a dose of 75 mg and 150 mg once daily respectively for 8 weeks as add-on therapy. Main outcome was change in blood pressure, metabolic parameters, renal function, inflammatory biomarkers, platelet aggregability and (UKPDS) United Kingdom Prospective Diabetes Study risk scoring.
Results: Significant decrease in blood pressure (P < 0.01), total cholesterol (P = 0.02), LDL (P < 0.01), triglyceride (P < 0.01) and a better glycemic control (P < 0.01) was found in clopidogrel group. Renal markers and electrolytes have been improved in clopidogrel group but in aspirin group there was deterioration (2.5%) of creatinine clearance. Clopidogrel group has shown a significant decrease in hsCRP (P < 0.01), UKPDS risk scoring (P < 0.01) and better anti-aggregatory effect.
Conclusions: Clopidogrel has prophylactic role in CKD with type 2 DM due to better control of metabolic parameters, renal function and inflammatory burden in comparison to aspirin. |
| first_indexed | 2024-12-10T23:24:15Z |
| format | Article |
| id | doaj.art-a5de07c00872476b93f280e7dacd70f8 |
| institution | Directory Open Access Journal |
| issn | 2008-7802 2008-8213 |
| language | English |
| last_indexed | 2024-12-10T23:24:15Z |
| publishDate | 2013-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | International Journal of Preventive Medicine |
| spelling | doaj.art-a5de07c00872476b93f280e7dacd70f82022-12-22T01:29:37ZengWolters Kluwer Medknow PublicationsInternational Journal of Preventive Medicine2008-78022008-82132013-01-0148902910Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: Comparison between clopidogrel and low-dose aspirinAmitabh DashRituparna MaitiTejaswi Kumar Akantappa BandakkanavarAmit BhaskarJai PrakashBajarang Lal PandeyBackground: Chronic kidney disease (CKD) coexisting with type 2 diabetes mellitus (DM) leads to coronary artery disease. The present study compares clopidogrel and low-dose aspirin as prophylactic therapy against coronary events in patients with CKD with diabetes. Methods: Total 80 patients of CKD with type 2 DM were randomized and allocated to clopidogrel and aspirin groups to receive the drug at a dose of 75 mg and 150 mg once daily respectively for 8 weeks as add-on therapy. Main outcome was change in blood pressure, metabolic parameters, renal function, inflammatory biomarkers, platelet aggregability and (UKPDS) United Kingdom Prospective Diabetes Study risk scoring. Results: Significant decrease in blood pressure (P < 0.01), total cholesterol (P = 0.02), LDL (P < 0.01), triglyceride (P < 0.01) and a better glycemic control (P < 0.01) was found in clopidogrel group. Renal markers and electrolytes have been improved in clopidogrel group but in aspirin group there was deterioration (2.5%) of creatinine clearance. Clopidogrel group has shown a significant decrease in hsCRP (P < 0.01), UKPDS risk scoring (P < 0.01) and better anti-aggregatory effect. Conclusions: Clopidogrel has prophylactic role in CKD with type 2 DM due to better control of metabolic parameters, renal function and inflammatory burden in comparison to aspirin.http://www.ijpvmjournal.net/article.asp?issn=2008-7802;year=2013;volume=4;issue=8;spage=902;epage=910;aulast=DashChronic kidney diseaseclopidogrellow-dose aspirintype 2 diabetes mellitus |
| spellingShingle | Amitabh Dash Rituparna Maiti Tejaswi Kumar Akantappa Bandakkanavar Amit Bhaskar Jai Prakash Bajarang Lal Pandey Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: Comparison between clopidogrel and low-dose aspirin International Journal of Preventive Medicine Chronic kidney disease clopidogrel low-dose aspirin type 2 diabetes mellitus |
| title | Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: Comparison between clopidogrel and low-dose aspirin |
| title_full | Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: Comparison between clopidogrel and low-dose aspirin |
| title_fullStr | Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: Comparison between clopidogrel and low-dose aspirin |
| title_full_unstemmed | Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: Comparison between clopidogrel and low-dose aspirin |
| title_short | Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: Comparison between clopidogrel and low-dose aspirin |
| title_sort | prophylactic add on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus comparison between clopidogrel and low dose aspirin |
| topic | Chronic kidney disease clopidogrel low-dose aspirin type 2 diabetes mellitus |
| url | http://www.ijpvmjournal.net/article.asp?issn=2008-7802;year=2013;volume=4;issue=8;spage=902;epage=910;aulast=Dash |
| work_keys_str_mv | AT amitabhdash prophylacticaddonantiplatelettherapyinchronickidneydiseasewithtype2diabetesmellituscomparisonbetweenclopidogrelandlowdoseaspirin AT rituparnamaiti prophylacticaddonantiplatelettherapyinchronickidneydiseasewithtype2diabetesmellituscomparisonbetweenclopidogrelandlowdoseaspirin AT tejaswikumarakantappabandakkanavar prophylacticaddonantiplatelettherapyinchronickidneydiseasewithtype2diabetesmellituscomparisonbetweenclopidogrelandlowdoseaspirin AT amitbhaskar prophylacticaddonantiplatelettherapyinchronickidneydiseasewithtype2diabetesmellituscomparisonbetweenclopidogrelandlowdoseaspirin AT jaiprakash prophylacticaddonantiplatelettherapyinchronickidneydiseasewithtype2diabetesmellituscomparisonbetweenclopidogrelandlowdoseaspirin AT bajaranglalpandey prophylacticaddonantiplatelettherapyinchronickidneydiseasewithtype2diabetesmellituscomparisonbetweenclopidogrelandlowdoseaspirin |